Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

Melanoma Clinical Trial

— Sportivumab  

Official title:

Sportivumab - Feasibility of Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03171064
• Other study ID #: Sportivumab/S-103/2017
• Status: Completed
• Phase: Phase 2
• Start date: September 5, 2017
• Est. completion date: December 1, 2022

Study information

• Verified date: May 2023
• Source: University Hospital Heidelberg
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Checkpoint inhibitors like the PD-1 antibodies Pembrolizumab and Nivolumab represent standard of care for patients with metastasized melanoma. Numerous high quality studies demonstrate that endurance and resistance training in cancer patients is safe and elicits beneficial effects. However, there is no systematic experience with regard to exercise interventions in patients undergoing checkpoint inhibitor treatment. Therefore, the Sportivumab Study aimed to investigate safety, feasibility and effectivity of a 12 week combined resistance and endurance exercise intervention program during checkpoint inhibitor treatment. It is planned to enroll 40 patients. Participants will be randomized into an experimental and a wait-list control group (20 per group). The wait-list control group will receive the exercise intervention program after week 13 of enrollment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 39
• Est. completion date: December 1, 2022
• Est. primary completion date: July 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients at age = 18 years

• Diagnosed with melanoma stage (independent of stage)

• Assigned to receive an immunotherapeutic regimen (PD-1 antibody +/- Ipilimumab)

• Sufficient German language skills

• Willing to train at the exercise facilities twice per week and to take part in the scheduled testing at the National Center for Tumor Diseases

• Signed informed consent

Exclusion Criteria:

• Any physical or mental conditions that would hamper the performance of the training programs or the completion of the study procedures

• Engaging in systematic intense exercise training (at least 1h twice per week)

Related Conditions & MeSH terms

• Exercise
• Melanoma
• PD-1 Antibodies

Intervention

Behavioral:
• Resistance and Endurance Exercise
Machine-based, 2x/week endurance and resistance training for 12 weeks

Locations

Country	Name	City	State
Germany	Heidelberg University Clinic	Heidelberg

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital Heidelberg	Department of Dermatology, Heidelberg University Hospital

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of the exercise intervention	Participants ability to fulfill the exercise prescription (measured by % of training frequency, intensity and duration as well as type of the exercise) during immune checkpoint inhibitor treatment with a PD-1 antibody +/- ipilimumab	During 12 week of the intervention
Secondary	Quality of life	Quality of life (QoL) will be assessed with the validated 30-item self-assessment questionnaire of the European Organisation for Research and Treatment of Cancer (EORTC QLQ-C30, version 3.0). It includes five multi-item functional scales (physical, role, emotional, cognitive, and social function), three multi-item symptom scales (fatigue, pain, nausea/vomiting), and six single items assessing further symptoms (dyspnea, insomnia, appetite loss, constipation, diarrhea) and financial difficulties.	During 12 week of the intervention
Secondary	Fatigue	Fatigue will be assessed with the Multidimensional Fatigue Inventory (MFI) which is a 20-item, multidimensional self-assessment questionnaire that has been validated for a German-speaking population.It covers five different dimensions of fatigue (general fatigue, physical fatigue, reduced activity, reduced motivation, and mental fatigue).	During 12 week of the intervention
Secondary	Sleep Quality	Sleep quality and sleep problems will be assessed with the validated and frequently used Pittsburgh Sleep Quality Index (PSQI).	During 12 week of the intervention
Secondary	Depression	Depressive symptoms are assessed with the 20-item Center for Epidemiological Studies Depression Scale (CES-D).	During 12 week of the intervention
Secondary	Physical Activity Behavior	Physical activity (PA) behavior in the domains of commuting activity, leisure time activities such as cycling, walking, and sports, household and occupational activity will be assessed via a standardized and validated questionnaire, the Short QUestionnaire to ASsess Health-enhancing PA (SQUASH) which has the advantage that it is short and easy to complete.	During 12 week of the intervention
Secondary	Cardiopulmonary Fitness	Cardiopulmonary fitness will be measured by assessing maximal aerobic capacity (VO2peak) via a maximal incremental cycling test with a quasi-ramp protocol starting at 20 watts and increasing by 10 watts every minute until volitional exhaustion. To control for test validity gas exchange will be measured using a breath-by-breath gas analysis system which will be calibrated according to the instructions of the manufacturer before each test. To monitor patient safety, a 12-lead electrocardiogram (ECG) will be and blood pressure will be measured prior, during and after testing. The criteria for exhaustion will be fulfilled if two out of three of the following criteria are valid: (1) Borg scale > 16; (2) peak heart rate ± 10% of age-appropriate reference value and/or (3) respiratory exchange ratio (RER) > 1.1. Exercise will be terminated prematurely in the case of major ECG abnormalities, severe dyspnea or excessive blood pressure increase (=250 mmHg systolic and/or =110 mmHg diastolic).	During 12 week of the intervention
Secondary	Muscle strength	Isometric (in four different joint angle positions) and isokinetic (at 60° angle speed) muscle capacity is measured with the Isomed 2000® diagnostic module (isokinetic evaluation and training machine). The protocol includes testing of representative muscles groups for upper (elbow flexors/extensors) and lower extremity (knee extensors/flexors)	During 12 week of the intervention
Secondary	Pain	The Brief Pain Inventory (BPI) is a 14-item questionnaire developed for use in patients with cancer that assesses worst pain, pain severity, and pain interference over the past week, reported on a scale of 0 to 10. Worst pain is categorized as mild (score of 3 to 4), moderate (score of 5 to 7), or severe pain (score of 8 to 10). Pain severity is measured as the average of responses to questions on worst pain, average pain, least pain, and pain right now. Pain interference is the average of seven interference items, such as walking, mood, and sleep.	During 12 week of the intervention